An interventional study of Avation System and Sham Avation System in Overactive Bladder, Urinary Urge Incontinence and Urge Incontinence, sponsored by Avation Medical, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Avation Medical, Inc. · Not applicable, Interventional, and Treatment
This is a prospective, multi-center, sham-controlled study comparing the safety and effectiveness of the self-adjusting, surgery-free, wearable Active System to a Sham System on adult Subjects diagnosed with OAB.
855 studies on the registry are indexed under Urinary Bladder, Overactive; 125 are open to participants now.
This study's enrollment of 125 is above the median of 72 across 652 interventional studies indexed under Urinary Bladder, Overactive.
Browse Urinary Bladder, Overactive studies →Avation Medical, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Avation System
Device: Avation System
Sham Avation System
Device: Sham Avation System
Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
The proportion of Subjects with a successful response
The proportion of Subjects with a successful response, where success is defined as: For enrolled Subjects that meet the inclusion criteria for average voids per day (frequency): a Subject that achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 4), in average voids per day relative to an upper normal limit of an average of 8 voids per day, or For enrolled Subjects that meet the inclusion criteria for incontinence events per day: a Subject that achieves a 50% or greater reduction from baseline (Visit 1) to Week 12 (Visit 4) in average incontinence events (IE) per day.
Time frame: Blinded Lead-In Portion of Study,12 Weeks
Quality of Life Endpoints: Questionnaires
Evaluation of the Subject Quality of Life questionnaires used throughout the duration of the trial.
Time frame: Length of Study, 24 months
Open-Label Phase Endpoints
During the Open-Label Phase, efficacy endpoints for enrolled Subjects that meet the inclusion criteria for average voids per day (frequency): a Subject that achieves a 50% or greater reduction, from baseline (Visit 1) in average voids per day relative to an upper normal limit of an average of 8 voids per day, or for enrolled Subjects that meet the inclusion criteria for incontinence events per day: a Subject that achieves a 50% or greater reduction from baseline (Visit 1) to in average incontinence events (IE) per day, except that Subjects initially enrolled in the Sham Arm will convert to Active Therapy (3x per week for 12 weeks followed by at least 1x per week for the remainder of the Study) and endpoints will be measured against their baseline (Visit 1) diary. .
Time frame: Length of Study, 24 months
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Avation Medical, Inc.